<DOC>
	<DOC>NCT01838369</DOC>
	<brief_summary>The purpose of this study is to investigate the effect of BI-505 on tumor burden in patients diagnosed with smoldering multiple myeloma.</brief_summary>
	<brief_title>A Phase II Study of BI-505 in Smoldering Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Diagnosis of Smoldering multiple myeloma based on the International Myeloma Working Group criteria: Serum Mprotein greater than or equal to 3 g/dL and/or bone marrow plasma cells greater than or equal to 10 percent. Absence of endorgan damage such as lytic bone lesions, anemia, hypercalcemia or renal failure that can be attributed to a plasma cell proliferative disorder. Male or female, 18 years or older. Eastern Cooperative Oncology Group (ECOG) Performance status of 01. Patients with a diagnosis of symptomatic multiple myeloma or a clinical suspicion of an ongoing progression into symptomatic multiple myeloma. Prior or current treatment having a proven or potential impact on myeloma cell proliferation or survival (including conventional chemotherapies, biological therapies, immunomodulatory drugs, or proteasome inhibitors), as judged by the Investigator. Severe other conditions.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>